ArticleWorld journal of gastrointestinal pharmacology and therapeutics2025
Risankizumab is effective following ustekinumab failure in Crohn's disease: A real-world study from a tertiary center.
Article in World journal of gastrointestinal pharmacology and therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Real-World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA Registry.Alimentary pharmacology & therapeutics · 2026Observational
- Outcomes of risankizumab use in adults with Crohn's disease in a real-world setting (ARISE-CD): a multicentre, retrospective cohort study.BMJ open gastroenterology · 2026Observational
- Understanding Remission of Long-Term Conditions Through Electronic Health Records: Scoping Review.Journal of medical Internet research · 2026Article
- Risankizumab redefines Crohn's treatment after ustekinumab failure.World journal of gastrointestinal pharmacology and therapeutics · 2026Article
- Comparative Effectiveness and Safety of Risankizumab vs Ustekinumab in Crohn's Disease: A Real-World Retrospective Cohort Study from Taiwan.Journal of inflammation research · 2026Article
- Acceptability and tolerability of risankizumab maintenance therapy administered via on-body injector in patients with Crohn's disease: Results of the ACCEPT-OBI study.Therapeutic advances in gastroenterology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCrohn's disease (CD) is a chronic immune-mediated inflammatory condition with significant morbidity. Several advanced therapies are now licenced for its treatment; however, data on superiority and optimal sequencing remain limited. The SEQUENCE trial demonstrated the superiority of risankizumab, a selective interleukin (IL)-23p19 inhibitor, over ustekinumab, an IL-12/23 inhibitor widely used in CD. Prior ustekinumab use may reduce risankizumab efficacy, and it remains unclear whether switching is effective in real-world practice, especially in refractory CD.
aimTo assess if in those with uncontrolled disease on ustekinumab, switching to risankizumab is effective.
methodsA retrospective review of electronic health records was conducted for adult CD patients at a tertiary center who switched directly from ustekinumab to risankizumab between December 2023 and September 2024. Disease activity was assessed using clinical [Harvey-Bradshaw Index (HBI)], biochemical [C-reactive protein (CRP), albumin, faecal calprotectin], and endoscopic parameters at baseline, 3, 6, and 9 months.
resultsFifty-one patients with a mean disease duration of 12.7 years were included. HBI decreased significantly at all timepoints (
conclusionSwitching from ustekinumab to risankizumab in active CD led to significant clinical and biochemical improvements and high remission rates, particularly in patients with SLOR. These findings support risankizumab as an effective option following ustekinumab failure in refractory CD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.